Robert D. Mass
Strategic AdvisorDr. Robert D. Mass, also known as Bob, M.D., serves as Strategic Advisor at Lite Strategy, Inc. (formerly known as MEI Pharma, Inc.) since May 03, 2021. He had been the Chief Medical Officer of Lite Strategy, Inc. (formerly known as MEI Pharma, Inc.) since June 1, 2011 until May 03, 2021 and was its Consultant since October 2010. Dr. Mass has experience as a Medical Oncologist in both clinical practice and clinical drug development. Dr. Mass joined MEI Pharma in 2010 after more than a decade at Genentech, where he played a leading role in the clinical development of blockbuster oncology drugs Herceptin?, Tarceva? and Avastin?. He held a number of leadership positions at Genentech from 1998 to 2009, lastly as Head of Medical Affairs, BioOncology. Previously, Dr. Mass served as Clinical Science Leader for Herceptin from 1999 to 2002, Tarceva from 2002 to 2003 and Avastin from 2003 to 2007. Prior to joining Genentech, he practiced Hematology and Medical Oncology from 1988 to 1998. Dr. Mass is certified by the American Board of Internal Medicine in both Internal Medicine and Medical Oncology. He earned his Bachelor?s degree in Economics from Tufts University and his Medical degree from Oregon Health & Science University.
Positions
- Company NameLite Strategy, Inc.Stock CodeLITSPositionStrategic Advisor
